Finally, animals treated with an agonist antibody to 4-1BB have been shown to induce high levels of CD8+ tumor-specific T cells and efficient antitumor immune response in vivo, which was mediated, in part, by increased survival of effector and memory CD8+ T cells upon activation [273]. The gene discussed is TNFRSF9; the disease is neoplasm.